Mayo Clinic, National Resilience to create center for biomanufacturing regenerative technologies

By The Science Advisory Board staff writers

August 16, 2022 -- The Mayo Clinic and biotech company National Resilience have announced a strategic collaboration in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions, with a focus on therapies derived from biologics for use in medicines.

Under the partnership, National Resilience will collaborate with Mayo's Center for Regenerative Medicine in Two Discovery Square within the research corridor of the Destination Medical Center economic development initiative in Rochester, Minn., according to the announcement.

The two organizations "will build embedded process and analytical development labs, as well as quality control labs" allowing for "closer proximity and collaboration to jointly develop and progress cell therapies and other advanced modalities into clinical care."

In addition to providing cell and gene products needed for biomanufacturing early-stage therapeutics, the goal is to attract biotech companies interested in sponsoring clinical trials at Mayo Clinic for novel regenerative biotherapeutics.

"Mayo is making significant investments in facilities to create the world's most advanced and innovative ecosystem for the development, manufacture, and delivery of biotherapeutics. We are seeking to build a community of innovators to explore ideas, develop new products and create thriving biotherapeutic companies," Julie Allickson, PhD, the Michael S. and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Medicine, said in a statement.

Copyright © 2022

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.